Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Does Naringenin Supplementation Improve Lipid Profile, Severity of Hepatic Steatosis and Probability of Liver Fibrosis in Overweight/Obese Patients With Nafld? a Randomised, Double-Blind, Placebo-Controlled, Clinical Trial Publisher Pubmed



Namkhah Z1 ; Naeini F1 ; Mahdi Rezayat S2 ; Mansouri S4 ; Javad Hosseinzadehattar M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Science, Tehran, Iran
  2. 2. Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. National Iranian Oil Company (NIOC) Health and Family Research Center, Tehran, Iran

Source: International Journal of Clinical Practice Published:2021


Abstract

Background and Objectives: Naringenin has been reported to have some promising pharmacological effects on the management of obesity and related metabolic complications including non-alcoholic fatty liver disease (NAFLD). Therefore, the present clinical trial study was done to assess the effects of naringenin supplementation on lipid profile, aminotransferase levels, severity of steatosis, as well as probability of fibrosis in overweight/obese patients with NAFLD. Materials and Methods: This placebo-controlled, parallel randomised, double-blind clinical trial study was conducted on 44 eligible overweight/obese patients with NAFLD (naringenin-treated group (n = 22), control group (n = 22)) referred to the national Iranian oil company (NIOC) Central Hospital, Tehran City, Tehran Province, Iran. Participants were randomly assigned to receive naringenin capsules (100 mg) and identical placebo capsules twice a day, before lunch and dinner, for 4 weeks. The primary outcomes were improvement of liver steatosis and NAFLD fibrosis score (NFS), and secondary outcomes included changes in levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and lipid profile. Results: Naringenin consumption significantly reduced percentages of NAFLD grades (P <.001), as well as, serum levels of triglyceride (TG) (P <.001), total cholesterol (TC) (P =.01), and low-density lipoprotein (LDL) (P =.02) and increased serum level of high-density lipoprotein (HDL) (P =.02) compared with the control group. Even after adjusting for the confounders, the results were significant. However, there were no significant changes in AST, ALT and NFS. Conclusion: Our findings revealed that daily intake of 200 mg of naringenin for 4 weeks had beneficial effects on lipid profile and percentages of NAFLD grades as an indicator for the severity of hepatic steatosis. Although, NFS values and serum levels of aminotransferase enzymes including AST and ALT did not remarkably change. © 2021 John Wiley & Sons Ltd
Related Docs
View other Related Docs
1. A Comprehensive Systematic Review of the Effects of Naringenin, a Citrus-Derived Flavonoid, on Risk Factors for Nonalcoholic Fatty Liver Disease, Advances in Nutrition (2021)
2. Effects of Naringenin Supplementation in Overweight/Obese Patients With Non-Alcoholic Fatty Liver Disease: Study Protocol for a Randomized Double-Blind Clinical Trial, Trials (2021)
3. Effects of Naringenin Supplementation on Cardiovascular Risk Factors in Overweight/Obese Patients With Nonalcoholic Fatty Liver Disease: A Pilot Double-Blind, Placebo-Controlled, Randomized Clinical Trial, European Journal of Gastroenterology and Hepatology (2022)
4. Naringenin, a Flavanone With Antiviral and Anti-Inflammatory Effects: A Promising Treatment Strategy Against Covid-19, Phytotherapy Research (2020)
5. The Association of the Adipokine Zinc-Alpha2-Glycoprotein With Non-Alcoholic Fatty Liver Disease and Related Risk Factors: A Comprehensive Systematic Review, International Journal of Clinical Practice (2021)
6. Naringenin: A Potential Flavonoid Phytochemical for Cancer Therapy, Life Sciences (2022)
7. Targeting the Vital Non-Structural Proteins (Nsp12, Nsp7, Nsp8 and Nsp3) From Sars-Cov-2 and Inhibition of Rna Polymerase by Natural Bioactive Compound Naringenin As a Promising Drug Candidate Against Covid-19, Journal of Molecular Structure (2023)
8. Effects of Oleoylethanolamide Supplementation on Inflammatory Biomarkers, Oxidative Stress and Antioxidant Parameters of Obese Patients With Nafld on a Calorie-Restricted Diet: A Randomized Controlled Trial, Frontiers in Pharmacology (2023)
Experts (# of related papers)
View all Related Experts
Mohammad Javad Hosseinzadeh Attar (6)
Seyed Mahdi Rezayat Sorkhabadi (2)
Other Related Docs
9. Metabolically Healthy and Unhealthy Obesity and the Progression of Liver Fibrosis: A Cross-Sectional Study, Clinics and Research in Hepatology and Gastroenterology (2021)
10. A Narrative Review on Therapeutic Potential of Naringenin in Colorectal Cancer: Focusing on Molecular and Biochemical Processes, Cell Biochemistry and Function (2024)
11. Effects of Oleoylethanolamide Supplementation on Atherogenic Indices and Hematological Parameters in Patients With Nonalcoholic Fatty Liver Disease: A Clinical Trial, Health Promotion Perspectives (2020)
12. The Association Between Major Dietary Patterns With the Risk of Non-Alcoholic Fatty Liver Disease, Oxidative Stress and Metabolic Parameters: A Case–Control Study, Journal of Diabetes and Metabolic Disorders (2022)
13. Triglyceride Glucose (Tyg) Index and the Progression of Liver Fibrosis: A Cross-Sectional Study, Clinical Nutrition ESPEN (2021)
14. Oleoylethanolamide Supplementation in Obese Patients Newly Diagnosed With Non-Alcoholic Fatty Liver Disease: Effects on Metabolic Parameters, Anthropometric Indices, and Expression of Ppar-Α, Ucp1, and Ucp2 Genes, Pharmacological Research (2020)
15. Curcumin and Inflammation in Non-Alcoholic Fatty Liver Disease: A Randomized, Placebo Controlled Clinical Trial, BMC Gastroenterology (2019)
16. Advancing the Global Public Health Agenda for Nafld: A Consensus Statement, Nature Reviews Gastroenterology and Hepatology (2022)
17. The Role of Gut Microbiota in Non-Alcoholic Fatty Liver Disease Pathogenesis, Obesity Medicine (2024)
18. Effect of a Moderately Carbohydrate-Restricted Diet on Liver Enzymes, Steatosis and Fibrosis in Normal-Weight Individuals With Non-Alcoholic Fatty Liver Disease: Study Protocol for a Parallel Randomised Controlled Clinical Trial, BMJ Open (2023)
19. Effects of Calorie Restricted Diet on Oxidative/Antioxidative Status Biomarkers and Serum Fibroblast Growth Factor 21 Levels in Nonalcoholic Fatty Liver Disease Patients: A Randomized, Controlled Clinical Trial, Nutrients (2022)
20. The Effects of Curcumin Supplementation on Liver Enzymes, Lipid Profile, Glucose Homeostasis, and Hepatic Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease, European Journal of Clinical Nutrition (2019)